These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15295300)

  • 41. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
    Barton M; Meyer MR; Haas E
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1669-72. PubMed ID: 17634518
    [No Abstract]   [Full Text] [Related]  

  • 42. Unopposed estrogen therapy and the risk of invasive breast cancer.
    Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
    Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?
    Mikkola TS; Clarkson TB; Notelovitz M
    Ann Med; 2004; 36(6):402-13. PubMed ID: 15513292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view.
    Speroff L
    Maturitas; 2004 Sep; 49(1):51-7. PubMed ID: 15351096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term postmenopausal hormone therapy and endometrial cancer risk: a study by Doherty et al.
    Odem RR; Moniz MH; Allsworth JE; Bleckman CR; Omicioli VA; Lawrence LT; Thaker PH
    Am J Obstet Gynecol; 2007 Aug; 197(2):213-4; discussion e1-5. PubMed ID: 17689656
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevent heart disease and osteoporosis at menopause.
    Healthc Demand Dis Manag; 1997 Mar; 3(3):33-8. PubMed ID: 10174592
    [No Abstract]   [Full Text] [Related]  

  • 49. Postmenopausal testosterone therapy and breast cancer risk.
    Somboonporn W; Davis SR
    Maturitas; 2004 Dec; 49(4):267-75. PubMed ID: 15531122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controversies regarding hormone therapy: Insights from inflammation and hemostasis.
    Koh KK; Yoon BK
    Cardiovasc Res; 2006 Apr; 70(1):22-30. PubMed ID: 16412400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract]   [Full Text] [Related]  

  • 52. [Hormone replacement therapy and cardiovascular risk in postmenopausal women].
    Kovacev-Zavisić B; Icin T; Kovacev N
    Med Pregl; 2009; 62 Suppl 3():85-90. PubMed ID: 19702123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Letter by Micheletti and Chevallier regarding article, "Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study".
    Micheletti MC; Chevallier T
    Circulation; 2007 Sep; 116(13):e362; author reply e363. PubMed ID: 17893283
    [No Abstract]   [Full Text] [Related]  

  • 54. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormone replacement therapy aggravates postmenopausal urinary incontinence.
    Prescrire Int; 2006 Aug; 15(84):137-8. PubMed ID: 16989027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Salpeter S
    Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S; Liebson PR; Klein LW
    Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002).
    Barber CA; Margolis K; Luepker RV; Arnett DK
    J Womens Health (Larchmt); 2004 Nov; 13(9):975-85. PubMed ID: 15665654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
    Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
    Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.